Bafna Pharmaceuticals (NSE:BAFNAPH) Short Interest


NSE:BAFNAPH Bafna Pharmaceuticals Ltd NSE:BAFNAPH
59 GF Score
Price ₹194.68
GF Value ₹90.54
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Bafna Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

NSE:BAFNAPH vs ZTS: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bafna Pharmaceuticals Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Bafna Pharmaceuticals's Short Interest falls into.


NSE:BAFNAPH
59GF Score
Bafna Pharmaceuticals Ltd NSE:BAFNAPH
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?

Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued. The current stock price of ₹194.68 is trading 115% above its estimated GF Value™ of ₹90.54. GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for NSE:BAFNAPH:

  • Short Interest:
  • GF Value™: ₹90.54 vs. price of ₹194.68 (115% above fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bafna Pharmaceuticals Business Description

Other Exchanges 532989:India
Address Thambu Chetty Street, New No. 68, Old No. 299, Bafna Towers, Chennai, TN, IND, 600001
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
59GF Score

Get the complete analysis for NSE:BAFNAPH

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹194.68
Price
₹90.54
GF Value